New oral antivirals against SARS-CoV-2 such as paxlovid have recently authorized.  In this manuscript we describe the evidence in the literature on the monotherapy use of paxlovid and monotherapy use of remdesivir, and the scientific hypothesis of using nirmatrelvir and remdesivir in association with the aim of increasing treatment efficacy, reducing the risk of adverse reactions and generating antiviral drug-resistant variants.
Paxlovid
Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.The efforts of the scientific world directed to identifying new antiviral drugs and therapies effective against SARS-CoV-2 continue.  Remdesivir is an authorized antiviral for the treatment of SARS-CoV-2 infection.  In this manuscript we describe the evidence in the literature on the monotherapy use of paxlovid and monotherapy use of remdesivir, and the scientific hypothesis of using nirmatrelvir and remdesivir in association with the aim of increasing treatment efficacy, reducing the risk of adverse reactions and generating antiviral drug-resistant variants.
Remdesivir
Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.The efforts of the scientific world directed to identifying new antiviral drugs and therapies effective against SARS-CoV-2 continue.  In this manuscript we describe the evidence in the literature on the monotherapy use of paxlovid and monotherapy use of remdesivir, and the scientific hypothesis of using nirmatrelvir and remdesivir in association with the aim of increasing treatment efficacy, reducing the risk of adverse reactions and generating antiviral drug-resistant variants.
Nirmatrelvir
Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.The efforts of the scientific world directed to identifying new antiviral drugs and therapies effective against SARS-CoV-2 continue.  Remdesivir is an authorized antiviral for the treatment of SARS-CoV-2 infection.  In this manuscript we describe the evidence in the literature on the monotherapy use of paxlovid and monotherapy use of remdesivir, and the scientific hypothesis of using nirmatrelvir and remdesivir in association with the aim of increasing treatment efficacy, reducing the risk of adverse reactions and generating antiviral drug-resistant variants.
Remdesivir